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Abstract
Introduction: Protein aggregation is a common cause of neuropathology. The protein aggregation myopathy
Limb-Girdle Muscular Dystrophy 1D (LGMD1D) is caused by mutations of amino acids Phe89 or Phe93 of DNAJB6, a
co-chaperone of the HSP70 anti-aggregation protein. Another DNAJB6 mutation, Pro96Arg, was found to cause a
distal-onset myopathy in one family.
Results: We detail the mutational, neuropathological, neurophysiological, neurological and radiological features of
five new DNAJB6-myopathy families. One has the known Phe93Leu mutation and classic late-onset slowly
progressive LGMD1D. Two have different mutations of Phe91 causing a variant childhood-onset severe limb-girdle
myopathy. One has a Phe100Val mutation and distal-onset myopathy, unique early bulbar involvement, and a
gender-modified wide age-of-onset range. The last has childhood-onset severe distal-onset myopathy and the first
non-missense DNAJB6 mutation, c.346 + 5G > A, causing a splicing defect that entirely eliminates DNAJB6’s G/F
domain (ΔG/F), the domain that harbours all other mutations. Clinical and imaging examinations reveal that
muscles considered uninvolved in DNAJB6-myopathy, e.g. lateral gastrocnemii, are affected in our patients with
new mutations. Mutational modelling based on the known structure of the bacterial DNAJ2 protein indicates that
all past and present mutated residues cluster within 15 Å in the G/F domain and all disturb the interface of this
domain with the protein’s J domain that confers the interaction with HSP70.
Conclusions: Our patients expand the phenotypic spectrum of DNAJB6-myopathy and allow tentative
genotype-phenotype specifications. Combining with previous studies, the clinical severity spectrum is as
follows: ΔG/F and Phe91 mutations, most severe; Phe100, Pro96, Phe89 mutations, intermediate; and Phe93,
least severe. As it stands presently, proximal G/F domain mutations (Phe89, Phe91, Phe93) cause proximal
limb-girdle myopathy, while distal G/F mutations (Pro96, Phe100) cause distal-onset myopathy. While all
mutations affect the G/F–J interaction, each likely does so in different unknown extents or ways. One mutation,
ΔG/F, causes its associated severe distal-onset myopathy phenotype in a clear way, through generation of a G/
F domain-lacking DNAJB6 protein.
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Introduction
Limb Girdle Muscular Dystrophy Type 1D (LGMD1D)
(also called Type 1E; OMIM #603511) is, by definition,
a limb girdle proximal muscle disease. Pathologically,
it is characterized by sarcomeric protein aggregates,
autophagic vacuolation and myofibrillar degeneration.
The genetic basis of LGMD1D was discovered in 2012,
namely mono-allelic mutations in the DNAJB6 gene
mapping to 7q36 [1, 2]. So far 20 families with
DNAJB6 mutations have been reported [1–5]. Of
these, 19 (98 patients) have the expected limb girdle
proximal muscle disease. One, an African American
family, does not. Instead all affected members of this
family have a distinctly distal myopathy [1].
DNAJB6 is ubiquitously expressed, including in skel-
etal muscle, though with highest expression in the
brain [6, 7]. DNAJB6’s best characterized function is
the participation with the heat shock protein HSP70
in preventing aggregation of misfolded or otherwise
aggregation-prone proteins including polyglutamine-
containing huntingtin, α-synuclein, TDP-43 and Aβ42,
through a process involving preferential interaction
with misfolding forms of these proteins [2, 6, 8, 9].
Connection of LGMD1D to DNAJB6 raised interest in
whether LGMD1D patients develop central nervous
system (CNS) disease in addition to their myopathy, and
in fact one patient (with a known DNAJB6 mutation) has
since been reported with pathologically confirmed fronto-
temporal dementia (FTD) and no mutation in any of the
known FTD genes [10]. Whether this is a coincidence or
other DNAJB6-myopathy patients will also develop FTD
with aging remains to be seen. Recently, the autophagic
vacuolation facet of LGMD1D led to the uncovering of an
association between DNAJB6 and Chaperone-Assisted
Selective Autophagy (CASA) components [2, 4]. A small
44 amino acid glycine/phenylalanine (G/F)-rich domain in
the central portion of the protein is critical to both this
association and the anti-aggregation function [2, 8, 9],
and, in fact, all DNAJB6 mutations to date (Phe89Leu,
Phe89Ile, Phe93Leu/Phe93Ile and Pro96Arg) are missense
mutations localized in this domain [1–5].
In 1999 a “distinctive autosomal dominant vacuolar
neuromyopathy” (OMIM #601846) was described in a
large Italian family with 10 affected members [11]. The
disease was characterized by variable age of onset (late
teens to early fifties) and severity, and by invariant ini-
tially exclusively distal leg weakness and wasting, which
later spread from distal to proximal muscles of upper
and lower extremities, and beyond, eventually involving
most muscle groups including facial and bulbar muscles.
Patients became dysphonic and dysphagic. Extraocular
muscles were spared. Muscle biopsies revealed rimmed
vacuoles. Genome-wide linkage analysis using microsat-
ellite markers established linkage with an 8 cM region in
chromosomal band 19p13 with a maximum two-point
LOD score of 3.03. Subsequent haplotype analyses re-
fined the locus to a 250 kb region [11, 12], but the mo-
lecular basis of this myopathy remains unknown.
Here we revisit the above family with next generation
sequencing and fail to find its molecular defect in the
small 250 kb region, or in the larger region of linkage in
chromosome 19. Instead, we identify a previously unre-
ported mutation in the G/F domain of the chromosome
7 DNAJB6 gene. We also study four sporadic cases with
myopathies with pathological features of LGMD1D.
Three of these patients have clinically typical LGMD1D
(proximal myopathy), in whom we find one known and
two novel DNAJB6 mutations. The fourth patient has a
distal myopathy and a so-far unique splice-site mutation
leading to complete loss of the DNAJB6 G/F domain.
Our work corrects the linkage of the distal myopathy
previously assigned to chromosome 19 and identifies its
cause. This family together with our patient with the spli-
cing mutation and the published African-American family
delineate the distal myopathy subphenotype of DNAJB6-
myopathy and establish tentative genotype–phenotype
(proximal versus distal myopathy) correlation in this
disease. Finally, our work indicates that complete loss of
the G/F domain function from the DNAJB6 protein under-
lies the distal form of the disease.
Materials and methods
Subjects
Patient investigations were conducted in accordance with
protocols approved by the institutional review boards of the
Carlo Besta Neurological Institute, Milan, the Policlinico
Tor Vergata of Rome, and The Hospital for Sick Children
of Toronto. Inclusion criteria for sporadic patients screened
for DNAJB6 mutations (n = 63) were: clinical diagnosis of
LGMD or distal myopathy, muscle histopathology charac-
terized by rimmed vacuoles and/or myofibrillar abnormal-
ities, serum CK values normal or slightly elevated and in
whom other conditions such as myofibrillar myopathies or
inclusion body myositis had been excluded by the appropri-
ate investigations.
Morphological studies
Patients III-3 and III-5 of family 1 underwent a diagnostic
biopsy of the deltoid muscle. Transverse cryostat sections
were routinely stained for: haematoxylin-eosin, Gomori tri-
chrome, periodic acid-Schiff, oil red O, myofibrillar ATPase,
acid phosphatase, NADH dehydrogenase, cytochrome C
oxidase, succinic dehydrogenase. Immunofluorescence for
phosphorylated tau-protein with anti-SMI-31 antibodies
(SantaCruz Biotechnology, Santa Cruz, CA, USA) and for
the autophagic protein sequestosome1 (SQSTM1, p62,
monoclonal sc-28359, Santa Cruz) with anti-p62 antibodies
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was performed. No muscle tissue was available for add-
itional immunochemical analyses.
On the muscle biopsies from sporadic patients
(quadriceps muscle in patients 1 and 3s, biceps in
patient 2s, deltoid in patient 4s), in addition to the
routine histochemical and immunohistochemical ana-
lyses, immunolocalization of several other proteins
was performed. Muscle cryosections were incubated with
one of the following antibodies: anti-DNAJB6 (rabbit
polyclonal PA5-21401, Thermo Fisher Rockford, IL, USA;
1:100), anti-LC3 (rabbit polyclonal PM036, MBL, Naka-ku,
Nagoya, Japan; 1:100), anti-p62 (guinea pig polyclonal
GP62-c, Progene Biotechnik, Heidelberg, Germany; 1:100;),
anti-transactive response element DNA-binding protein of
43 kDa (TDP-43) (rabbit polyclonal 10782-2-AP, Protein-
tech Chicago, IL, USA; 1:200), anti BAG3 (mouse
monoclonal sc-136493, SantaCruz; 1:50) followed by incu-
bation in Alexa 546- or Alexa 488-conjugated goat anti-
mouse, anti-rabbit, or anti-guinea pig IgG (Invitrogen Life
Technologies, Carlsbad, CA, USA) as appropriate, 1:2000,
for 2 h. As control, sections were either incubated with
rabbit non-immune serum, or with isotype-specific non-
immune IgG (Dako, Copenhagen, Denmark), or the pri-
mary antibody was omitted.
For co-localization studies muscle cryosections were in-
cubated in a mixture of primary antibodies; either DNAJB6
(monoclonal, Sigma Aldrich, St. Louis, MO, USA; 1:100)
plus TDP43, or desmin (monoclonal M0760, Dako; 1:200)
plus p62, or desmin (rabbit polyclonal A0611, Dako, 1:100)
plus myotilin (monoclonal NCL-MYOTILIN, Novocastra,
Newcastle-upon-Tyne, UK; 1:20), or p62 plus poly-
ubiquitinylated proteins (monoclonal PW8810, clone FK2
from Biomol, Enzo Life Sciences, Inc. Farmingdale, USA;
1:200), or desmin plus SMI-31 (monoclonal SMI-31R,
Covance Research Products, Princeton, New Jersey, USA;
1:100) followed by washes and incubation in a mixture of
appropriate fluorescent dye-conjugated secondary anti-
bodies. Muscle sections were examined under either a
Zeiss Axioplan fluorescence microscope (Carl Zeiss
AG, Oberkochen, Germany) or a Leica confocal micro-
scope equipped with hybrid and argon lasers (Leica
Microsystems, Wetzlar, Germany). Muscle biopsies from
X-linked myopathy with excessive autophagy (XMEA),
Pompe disease (PD) and GNE-mutated inclusion body
myopathy patients were used as positive controls.
Western blotting
Muscle cryosections were solubilized in 25 μl lysis
buffer containing 4 % SDS, 125 mM Tris–HCl pH 8.8,
40 % glycerol, and 0.5 mM PMSF; sonicated, boiled,
and centrifuged at 15,000 g for 5 min. Samples of
supernatant were electrophoresed on 7.5 % or 15 %
SDS-PAGE and transferred onto nitrocellulose mem-
branes. Membranes were probed with antibodies to
DNAJB6 (1:500), TDP-43 (1:250), LC3 (1:500), or p62
(1:800). Vinculin (1:1000; Sigma) was used as indicator
of how much muscle protein was loaded. Blocked
membranes were then incubated in biotin-conjugated
secondary antibody (1:2500; Jackson ImmunoResearch
Laboratories, Inc., Westgrove PA, USA), followed by
peroxidase-conjugated streptavidin (1:3000, Jackson
ImmunoResearch) and by detection with the ECL
chemiluminescence reagent (Amersham Biosciences,
Buckinghamshire, UK).
Linkage analysis
Four members of family 1 with unambiguous clinical
presentation were genotyped using the Illumina
HumanCoreExome Beadchip (Illumina, Inc.) following
manufacturer’s instructions. Pruning of SNPs was per-
formed with PLINK software (http://pngu.mgh.harvar-
d.edu/purcell/plink/) [13] and the set of SNPs obtained
was used for parametric linkage analysis with the MERLIN
software v1.1.2 [14]. A dominant model with penetrance
0.0001, 1.0, 1.0 (wild type, hetero and homozygous alleles)
was applied, calculating the LOD score for a 1 cM grid
along the chromosomes at disease allele frequency of
0.0001.
Exome sequencing
Exome sequencing was performed on two affected and
one healthy relative (III:2, III:3 and III:5) as follow. Target
enrichment was performed using Life Technologies Ion
AmpliSeqExome Library kit according to manufacturer’s
instructions. Amplified DNA was then processed for
Proton sequencing. Ion PI Template OT2 200 kit v2 (Life
Technologies) was used to immobilize and amplify mono-
clonally single stranded amplicon molecules on Ion
Sphere Particles XT (ISP-XT). Sequencing was performed
with the Ion Torrent Proton System using the Ion PI
Sequencing 200 Kit v2 (Life Technologies). Raw signal
processing, base calling, alignment and germline (diploid)
variant detection was performed using Lifetech’s Torrent
Server v3.6 (Life Technologies). Alignment of reads to the
human genome reference hg19 (NCBI build GRCh37) was
performed using Tmap 3.4.0 and single nucleotide and
small insertion/deletion variant calling was performed
with Torrent variant caller 3.6. The resulting variant call
file (vcf) containing SNV and indels was annotated using
a combination of SNPEff (http://snpeff.sourceforge.net/)
and ANNOVAR [15]. Variants were filtered by screening
against public single nucleotide polymorphism databases
including dbSNP (http://www.ncbi.nlm.nih.gov/projects/
SNP/) 1000 genomes project (http://www.1000genome-
s.org) and NHLBI Exome Sequencing Project (ESP) Exome
Variant Server (http://evs.gs.washington.edu/EVS/). Novel
SNVs were also annotated with SIFT [16] and PolyPhen-2
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[17] scores to predict putative effects of variants on protein
function.
Sanger sequencing
Sanger sequencing was performed to verify and validate
the variant segregating in the family and to identify mu-
tations in sporadic cases. Genomic DNA was analysed
by polymerase chain reaction (PCR) using oligonucleo-
tide primers designed to amplify coding region, intron-
exon junctions, and 1000 bp of the 5’ flanking sequence
of the DNAJB6 gene (GenBank NC_000007.14). PCR
products were sequenced using the BigDye Terminotor
Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) and an ABI Prism 3100 Genetic Analyzer
(Applied Biosystems). Pathogenicity predictions for
variants were obtained from Mutation Tester (http://
doro.charite.de/MutationTaster/), SIFT (http://sift.jcvi.
org/www/SIFT_enst_submit.html), or PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/). Sanger sequencing was
also performed on DNA from all the available family
members of sporadic patients.
RNA analysis
To detected alternative transcripts due to splice-site muta-
tions, total RNA was isolated from muscle samples using
TRI Reagent (Ambion, Austin, TX, USA) according to the
manufacturer’s instructions, and checked for quantity and
purity using a Nanodrop 2000C spectrophotometer
(Thermo Scientific, Waltham, MA, USA). Aliquots of
RNA (1 μg) were reverse-transcribed in the presence
of 5× first strand buffer (Life Technologies, Carlsbad,
CA, USA), 1 mM each deoxynucleoside triphosphate,
8 pM random hexamers, 10 μM dithiothreitol, 1 IU/μl
RNAse inhibitor (Roche Molecular Biochemicals, Basel,
Switzerland), and 10 IU/μl M-MLV reverse transcriptase
(Life Technologies), by incubation at 37 °C for 1 h and at
95 °C for 5 min. The resulting cDNA was amplified using
appropriate primers, purified from agarose gel, using
QIAquick Gel Extraction kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions and
verified by sequencing.
Molecular modelling
Secondary structure prediction was made with PSIPRED
[18] and disordered regions prediction with Robetta
[19]. Both analyses suggest that the G/F domain has low
structural complexity and contains a single helix that is
preceded and followed by unstructured regions. The C-
terminal domain of the protein is instead predicted to
adopt a β structure. A search for evolutionary related
homologues to DNAJB6b was performed with Phyre2
[20] and I-Tasser [21]. The initial homology model was
obtained with Phyre2, using TtDNAJB2 as a template
(pdbcode: 4 J80) and then energy minimized with
Modeller version 9 [22]. It covers residues 2–125 of
DNAJB6, which comprise the J domain, the G/F
domain and its junction with the C-terminal domain.
Ramachandran statistics were calculated with Pro-
check [23]. The geometrical quality of the model is
good with 91.2 % of residues lying in the most
favoured regions of the Ramachandran plot, 7.8 % in
additionally allowed regions and 1 % (1 residue: Ser81)
in disallowed regions. Site specific mutations were
inserted with COOT [24]. All structure representa-
tions in Fig. 8 were prepared with PyMol (The PyMOL
Molecular Graphics System, Schrödinger, LLC).
Results
Clinical and radiological findings
Family 1 (previously thought to be linked to chromosome
19). Ten members of this family were previously consid-
ered affected. Eight of these (7 male, 1 female) have/had
an unequivocal myopathy, which is inexorably progressive.
Three, individuals II:2, III:1 and III:2 (see Fig. 1), in the
original study [11] had a ‘particularly benign phenotype
with very mild distal leg weakness and hypotrophy…’ Of
these three one has since died, but the other two (III:1 and
III:2) were available for re-review. With 15 years hindsight
we can see that these individuals have had absolutely no
progression, and are clearly not affected by the same
syndrome afflicting their cousins.
Of the eight truly affected members of the family
(filled symbols in family 1 in Fig. 1), five were alive
and re-analyzed. Table 1 summarizes their clinical and
laboratory findings. The typical pattern of muscle
involvement is weakness and atrophy initiating in the dis-
tal muscles of the lower limbs and propagating to virtually
all other districts, including facial and bulbar muscles, but
sparing extra-ocular muscles. Foot dorsiflexor weakness
was the only sign in the youngest patient (individual IV:4).
Age at onset varied greatly (10 to 50 years of age). In
particular, the one affected female (individual II:6) had a
very late onset.
MRI of the lower limbs was performed in patient III-3
at age 52, 22 years after disease onset, and in patient III-5,
again at age 52, 25 years after onset. Both were ambulant,
at least indoors. MRI showed severe to almost complete
fatty infiltration of lateral and medial gastrocnemii, and of
the thigh muscles, in particular the vasti, adductor
magnus, semitendinosus, semimembranosus and biceps
femoris. Less relevant fatty infiltration was present in
soleus and tibialis muscles (Additional file 1: Figure S1).
Sporadic patients
In three sporadic patients (1, 2 and 3s, Fig. 1) the initial
symptom consisted of weakness predominantly in the
muscles of the pelvic girdle, while in a fourth patient
(patient 4s) the first manifestation was weakness in the
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lower limb distal muscles (Table 1). In patient 2s with
onset at 11 years severe ventilatory failure occurred at
age 57 requiring non-invasive ventilation, and severe
dysphagia requiring percutaneous endoscopic gastros-
tomy. None of the patients had facial or tongue weak-
ness, diplopia, ophthalmoparesis or ptosis. None had
cardiac involvement, except for subaortic stenosis in
patient 2s detected at age 57, and left ventricular
hypertrophy on echocardiography in patient 3s at age
55 consistent with his hypertension. Family history
was negative in all 4 sporadic patients.
Patients 1 and 2s underwent computed tomography
(CT) examination at the age of 37 and 40, 21 and
29 years after disease onset, respectively. Both had pres-
ervation of anterior thigh muscles with the exception of
vastus lateralis which was completely substituted and of
soleus and medial and lateral gastrocnemius. CT of
patient 3s at 52 years disclosed involvement of adductor
magnus and biceps femoris along with peroneus and
gastrocnemii. Patient 4s had an MRI 2 years after loss of
autonomous walking (33 years after disease onset),
which revealed fatty substitution of all anterior right
thigh muscles and of rectus femoris and vastus medialis
in the left thigh, while vastus intermedius and lateralis
muscles were less severely infiltrated. Biceps femoris and
semitendinosus were relatively preserved. Asymmetric
involvement was also present; left soleus was less
involved, while all other muscles in both legs were
infiltrated.
Morphological findings
In all muscle biopsies the prevalent alterations were
myopathic atrophy and hypertrophy, increased number
of internalized myonuclei, necrosis and regeneration,
and fibro-fatty substitution. However, the most typical
finding was presence of sarcoplasmic vacuoles with
basophilic rim, and some eosinophilic inclusions
(Fig. 2). Immunofluorescence for phosphorylated tau
was negative, whereas anti-p62 antibodies specifically
decorated sarcoplasmic inclusions with various intra-
cellular distribution (Fig. 3).
Both in family 1 and in the sporadic patients, in addition
to rimmed vacuoles in a variable number of fibers, there
was also extreme variability of fiber diameters, focally
reduced activity of oxidative enzyme staining and increased
acid phosphatase activity surrounding the vacuoles (Fig. 2).
Limitation of muscle tissue from family 1 did not allow
additional studies, which were possible in the sporadic
cases. In the latter, DNAJB6, by immunofluorescence, was
expressed at the peripheral rim of most nuclei, in the
Fig. 1 Pedigrees of family 1 and sporadic patients
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Table 1 Clinical, neurophysiological, pathological and radiological features of affected individuals
Patient ID II-6 III-3 III-5 III-8 IV-4 Patient 1s Patient 2s Patient 3s Patient 4s
Sex F M M M M F F M F
Age at onset 50 y 30 y 27 y 10 y 20 y 16 y 11 y 45 y 6 y
Onset symptoms Difficulties in climbing
stairs
Impossibility to jump Difficulties in
climbing stairs
Bilateral foot drop
Age last seen 79 y 52 y 52 y 47 y 22 y 39 y 40 y (now 59 y) 57 y 39 y
Upper limb proximal
weakness





moderate medium grade severe absent medium grade severe absent medium grade
Lower limb proximal
weakness
severe medium grade severe severe absent severe severe medium grade severe
Lower limb
distal weakness
severe medium grade severe severe moderate severe severe medium grade severe
Ambulant No Yes Yes No Yes No (lost at 30 year) No (lost at 40 year) Yes No (lost at 37 years)
Facial weakness moderate moderate absent moderate absent absent absent absent absent
Dysarthria Yes Yes Yes Yes No No Yes No No
Dysphagia Yes Yes Yes Yes No No (occasional





Dysphonia Yes No Yes Yes No No No No No















































Thigh and leg diffuse
substitution (relatively
less relevant in left
semitendinosus, biceps
and soleus)
CK n.p. 4x 1.5x n.p. n.p. normal 1.2x 1.5x 1.1x













































cytoplasm of fibers, localized at the Z discs (when observed
in longitudinal fibers), and on the surface and within
inclusions of vacuolated fibers (Fig. 3); LC3 positivity was
detected in the lumen and on the rim of vacuoles and in
subsarcolemmal sarcoplasmic inclusions (Fig. 3), p62 was
strongly expressed as aggregates in and around vacuoles, as
dots in the cytoplasm of a few fibers and as a rim delimiting
the surface of rare fibers (Fig. 3). TDP-43 was similarly
expressed and co-localized with the p62 signal (Fig. 3), and,
in addition, was expressed in nuclei. Desmin was normally
expressed in the intermyofibrillar network, myotilin was
observed in several positive sarcoplasmic aggregates in a
few fibers (Fig. 3), and SMI-31 was expressed within few
vacuoles (not shown). BAG3 expression was increased in
the cytoplasm of vacuolated and atrophic angulated fibers
and within aggregates, often co-localizing with p62 (Fig. 3).
Western blot analysis
By Western blotting both DNAJB6 long and short iso-
forms were expressed in patient muscle biopsies except
in patient 1s in whom all muscle proteins were ex-
tremely reduced (Fig. 4). We did not observe obvious
differences in expression of LC3, p62 or TDP-43 com-
pared to control muscles (not shown), probably because
the technique fails to reveal changes that are present in
a small number of fibers.
Genetic analysis
In family 1, SNP based linkage analysis identified 18 gen-
omic regions with LOD scores ≥ 1. Among 22 meaningful
variants found in these regions by exome sequencing after
application of filters, a heterozygous missense variant
c.298 T >G causing a Phe100Val change in the chromo-
some 7 DNAJB6 gene (NM_058246.3) was noted (Fig. 5).
Sanger sequencing confirmed this variant in heterozygous
state in all affected members. The variant is novel and not
reported in variant databases such as 1000 Genomes,
Exome Server Project (ESP), dbSNP142 and the EXAC
browser (http://exac.broadinstitute.org/). It falls in the
highly conserved region of the DNAJB6 G/F domain.
Predictive software tools such as SIFT, PolyPhen-2 and
Mutation Taster, suggested a strong deleterious effect on
the protein. Finally the phenylalanine in this position is
conserved through evolution from xenopus to human.
Fig. 2 Histopathological characterization of muscle biopsies in patients III:5, and 1 to 4s, showing, by H&E and Gomori trichrome stains, rimmed
vacuoles, internalized myonuclei, and variability of fiber diameters in all patient muscles; by acid phosphatase staining, increased activity
surrounding vacuoles in patient 3s
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The variant was absent from all healthy relatives, except
one, individual IV:3 (age 30 years). This female individual
carries the mutation but is not yet clinically affected. As
mentioned, her grandmother, individual II:6 and the only
affected female in the family, was not affected until age 50.
Individuals III:1 and III:2 do not carry the mutation. Of
note, no variants were present in the 8 cM chromosome
19 region delimited by the original study [11], i.e. between
D19S209 to D19S177. Moreover no known vacuolar
myopathy genes including GNE, DES, MTR3,VCP, MYH2,
FLNC, TCAP, ANO5 and NEB had any variants in the
exome results. TTN did show three common previously
reported benign variants.
In the sporadic cases we detected by Sanger sequen-
cing one previously reported missense mutation [1, 2],
c.279C > G p.Phe93Leu in patient 3s. Patients 1 and 2s
had novel mutations, c.271 T > A p.Phe91Ile, and
c.273C > G p.Phe91Leu, respectively, affecting the same
amino acid. In patient 4s we found an intronic change,
c.346 + 5G > A, in the consensus splice site sequence.
RNA analysis in this patient revealed a normal band and
a band of lower molecular weight that, by sequencing,
was missing the entire exon 5, which encodes the G/F
domain (Fig. 5). This mutation is termed ΔG/F in the
remaining text. All the mutations were checked also in
available family members. None had the corresponding
variants, i.e. all were de novo mutations. Other vacuolar
myopathy related genes previously ruled out in these
sporadic patients by Sanger sequencing were: GNE and
ANO5 for patient 1s, GNE for 2s, GNE, ANO5 and
MYH7 for 3s and GNE for 4s.
Mutation molecular modelling
DNAJB6 belongs to the Type II subfamily of Hsp40
proteins, whose structure can be roughly divided into
three functional domains: the conserved N-terminal J
domain, the G/F domain, and a variable C-terminal do-
main [25]. The above results, combined with all previous
published cases [1–5], reveal that mutations of Phe89,
Phe91 and Phe93 are associated with proximal-onset
myopathy, while mutations of Pro96 (Pro96Arg, the
African-American family mentioned above) and Phe100,
and ΔG/F, result in distal-onset myopathy.
To gain possible insights into mutation-dependent
phenotypic differences we obtained a homology model
for DNAJB6. We interrogated the Phyre2 [20] and I-
Tasser [21] servers for structural homologues and both
identified the Thermus thermofilus DNAJ2 protein
(TtDNAJ2; pdb code: 4 J80) [26] as the closest
DNAJB6 homologue of known structure, with 100 %
confidence in the evolutionary relationship between
the two proteins (Phyre2). Fig. 6a shows the alignment
Fig. 3 Immunolocalization of various proteins in patients 1 to 4s and III:3, showing that DNAJB6 staining is present on the rim of nuclei and in
the cytoplasm of the fibers, where it co-localizes at the z discs with desmin, and on the surface and cytoplasmic inclusion of vacuolated fibers;
desmin is normally expressed; myotilin is present in few inclusions in rare fibers; LC3 is present in the lumen and on the rim of vacuoles and in
subsarcolemmal sarcoplasmic inclusions; p62 is present in sarcoplasmic inclusions and vacuoles with variable intracellular distribution and
co-localizes with TDP43 and with BAG3
Fig. 4 Western blot of DNAJB6 protein in muscle homogenates
from sporadic patients compared to control showing both
DNAJB6 isoforms
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Fig. 5 a–e) Electropherograms showing the mutations in genomic DNA from patients II:6 and patients 1 to 4s. f Agarose gel showing the
alternative transcript in patient 4s’ cDNA compared to control, and (g–i) sequences confirming skipping of exon 5, which encodes the G/F
domain, in the smaller cDNA band and loss of amino acid 79_115 coded by exon 5
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Fig. 6 (See legend on next page.)
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of DNAJB6 and TtDNAJ2 comprising the J and G/F
domains and the junction between the latter and the
C-terminal domain. The homology model was thus
built, on the basis of the Phyre2 alignment, with
TtDNAJ2 as a single template, and then energy mini-
mized using Modeller [22] (Fig. 6b). We did not model
the C-terminal domain because no clear consensus could
be derived in this region by the alignment programs.
The G/F domain is predicted to be composed of an
α-helix and flanking loops. Pro96 and Phe100 are in
the α-helix, while Phe89, Phe91 and Phe 93 are in the
upstream loop. In the model, the G/F domain folds as a
spiral onto the J domain with which it makes widespread
contact, mediated through phenylalanine residues, includ-
ing Phe91, Phe93 and Phe100 (Fig. 6c). Conservative re-
placements of these phenylalanines are predicted by the
model to disrupt or weaken the G/F – J domain interac-
tions (Fig. 6d, e and f). Replacement of Pro96 with arginine
is likewise predicted to destabilize the G/F – J interface be-
cause of arginine’s positive charge and cumbersome side
chain compared to proline’s (Fig. 6e). Phe89 is predicted to
have a somewhat different impact as it does not directly
interact with the J domain. Rather, its side chain protrudes
inside the spiral formed by the G/F domain where it makes
hydrophobic interactions, among which a stacking inter-
action with Phe104 which if lost would destabilize the G/F
spiral (Fig. 6g). Overall, the homology model suggests that
all mutated residues cluster in the same area of the G/F do-
main. The model also suggests that mutations, even when
conservative, might all disturb the J-G/F interdomain inter-
actions or destabilize the G/F domain, or both.
Discussion
Proximal versus distal onset myopathy – DNAJB6 muta-
tions established causation in LGMD1D [1, 2]. In these
original and subsequent publications all mutations in all
cases with limb girdle myopathy were missense and all
were in the encoded protein’s G/F domain, specifically in
the codons of amino acids 89 and 93 [1–5]. In one of
the two original reports, one of the families (mutation
Pro96Arg) did not have a limb girdle myopathy but a
distal myopathy [1]. In the present report, two of our
sporadic cases (1 and 2s) have novel missense mutations
affecting the codon of amino acid 91. Our third sporadic
case (3s) has a known mutation of amino acid 93. All
three have limb girdle myopathy. On the other hand,
affected members of our family 1 have a mutation in
amino acid 100 and manifest a distal-onset myopathy.
As such, as of now, all published cases with mutations in
amino acid 93 and proximal have a proximal, limb gir-
dle, myopathy, while cases affecting the more distal
amino acids 96 and 100 have a distal myopathy. Finally,
our sporadic case with ΔG/F has a distal myopathy,
suggesting that the clinical effect of mutations in the
distal amino acids 96 and 100 is more similar, at least in
regards to the order of clinical progression, to loss of the
G/F domain.
Sex effect – In our family 1, six of seven affected indi-
viduals are male and the one female (II:6) has a much
later onset (Fig. 1 and Table 1). In one sibling pair in the
family (IV:4 and IV:3), the male (IV:4) is affected at age
22, whereas the female (IV:3), who also carries the muta-
tion, is still unaffected at 30. We counted the affected
males and females in the published literature [1–5],
including ours, and find that males outnumber females
71 to 46 (3:2). These results suggest a gender modifier
in DNAJB6-myopathy due to the Phe100Val mutation.
In our other, sporadic, patients we could not perform a
similar analysis and the generalizability of the sex effect
awaits study of multiplex families with the other DNAJB6
mutations.
Age of onset and severity – Our patient with the previ-
ously known Phe93Leu had his onset at age 45, progressed
slowly and is still ambulatory at age 57 (Table 1), consistent
with the classic adult onset LGMD1D phenotype and all 49
previously reported cases with this mutation [1, 2, 4].
The other previously published mutations in LGMD1D
were both in amino acid 89 (Phe89Ile and Phe89Leu), and
with these mutations onsets in both adulthood and
childhood (as young as age 8) were reported, with a
disease course somewhat more rapid than the de-
scriptions of Phe93Leu/Phe93Ileu patients, indicating
(See figure on previous page.)
Fig. 6 Putative structure of DNAJB6b J and G/F domains obtained through homology modelling using the structure of TtDNAJ2 (pdbcode: 4 J80)
as template. a Alignment of DNAJB6b and TtDNAJ2 highlighting the J and G/F domains. Identical residues are shown in bold, residues found
mutated in patients are highlighted in red. b Ribbon representation of the homology model of DNAJB6. c A detail of the interface between J
and G/F domains. The J domain is represented in surface and colored according to its electrostatic properties (blue for positive and red for
negative charge, respectively) while the G/F domain is shown in cyan ribbon. Phenylalanine residues found at the interface are shown in sticks. d
Detailed view of the interactions played by Phe100. Its corresponding valine residue found in patients is shown in magenta. The J domain is
represented in blue while the G/F domain is represented in cyan. Residues close to Phe100 are also shown in sticks; Phe100 is predicted to
establish interactions with both J domain residues (Val55, Lys61 and Ile64) and G/F domain residues (His82 and Val99). e Detailed view of the
Phe93Leu mutation; Phe93 is predicted to establish a cation-π interation with J domain residue Lys47 and hydrophobic interactions with G/F
domain Pro96. Pro96 faces the J domain helix III and its mutation to arginine is linked to distal-onset phenotype. f Detailed view of the Phe91Leu
mutation; interacting residues are also shown. g Detailed view of the Phe89Ile mutation. Phe89 does not directly contact the J domain; rather it
protrudes inside the G/F domain spiral where it is predicted to interact with Phe104. Color codes in (e, f and g) panels are the same as in (g)
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that Phe89Ile/Phe89Leu are somewhat more severe
than Phe93Leu/Phe93Ileu.
Both our cases with the novel Phe91Ile and Phe91Leu
mutations have childhood onset disease (16 and
11 years-old respectively), and one of them (patient 2s;
Phe91Leu) has had a relatively severe course. She lost
ambulation at age 40, had major respiratory difficulties
since age 52, requiring daily nocturnal non-invasive
ventilation since age 57, and severe swallowing difficulty
with consequent marked weight loss necessitating gastric
feeding at age 58. It appears that patient 1s (Phe91Ile) is
following a similar severe course; she is already non-
ambulant at age 30 (Table 1).
Our patients with Phe100Val mutation and distal-
onset myopathy have a range of ages of onset (10 to
50) and severity, as mentioned. Additionally, they have
dysphagia and early bulbar involvement with dysarth-
ria, dysphonia and tongue atrophy, features not seen
with any other mutations. The only other cases with a
missense mutation and distal-onset myopathy (Pro96Arg)
had a range of age of onset from 18 to 35.
Our patient with ΔG/F and distal-onset myopathy
(4s) has the earliest onset DNAJB6 myopathy pheno-
type reported to date (age 6). Her progression appears
to be following the severe course of the Phe91 cases.
She lost ambulation at 37 years and at 39 years has
commenced to have respiratory difficulties (Table 1).
Conclusions
In summary, it appears that the range of severity in
DNAJB6 myopathy in presently known mutations is as
follows: ΔG/F and Phe91 mutations, most severe –
Phe100Val, Pro96Arg and Phe89 mutations, intermediate
severity – Phe93 mutations, least severe. This obviously
awaits confirmation in larger numbers of patients.
Skeletal muscle imaging – Following the reporting of
the first LGMD1D DNAJB6 mutations, Udd and
colleagues published a detailed muscle MRI study of the
disease. Only their European (Finnish and Italian) cases
were included, as their American families were older
cases without adequate imaging available. As such, all
the patients studied had the Phe93Leu mutation. The
authors reported the radiological features of these cases
in both early and late phases of the disease, disclosing
a pathognomonic pattern of muscle involvement for
this mutation - early stages: ‘soleus, adductor magnus,
semimembranosus and biceps femoris muscles followed
by medial gastrocnemius, adductor longus and later by
vasti muscles of the quadriceps. Rectus femoris, lateral
gastrocnemius, sartorius, gracilis and the anterolateral
group of the lower leg muscles were spared until late
senescence [27]. In our present cases, the Phe93Leu
patient fits the above pattern. To our knowledge one
other study reporting MRI findings has been published,
namely several Japanese patients with Phe93Ile, with
findings comparable to the Phe93Leu cases [4]. In our
current other patients with more severe, or with distal
onset disease, the recti, sartorii, gracilis and anterolateral
groups did show relative sparing, but the lateral gastro-
cnemii were seriously involved in all patients including
in less advanced stages of disease.
DNAJB6 mutations explain 6.4 % of our collection
of genetically undefined vacuolar and myofibrillar
myopathies – DNAJB6 mutations were present in 4 of
63 of our patients followed at the Besta Neurological
institute with LGMD or distal phenotype, muscle histo-
pathology characterized by vacuolation and/or myofibril-
lar abnormalities, and no mutations in the known genes
associated with these pathologies. Additional genes
therefore remain to be identified in these myopathies.
Functional insights – Evidence strongly suggests that
DNAJB6-myopathy mutations are gain-of-deleterious-
function mutations. Protein mutated at Phe89, Phe93
and Pro96, or lacking the G/F domain (ΔG/F), intro-
duced into yeast and zebrafish models, in amounts
equimolar to wild-type their counterpart, have toxic
consequences consistent with the disease pathology [2,
9]. Canonically, J domain containing proteins interact
with target misfolding proteins through their C-
termini and then with HSP70 through the J domain,
which initiates processes of either restabilizing the tar-
get or escorting it to degradation [28]. While it is
unclear whether DNAJB6 follows this precise rule, it is
abundantly clear that the protein prevents aggregation
of varied misfolding-prone proteins [6, 8, 9]. The
DNAJB6 G/F spiral folds upon and makes what appear
to be crucial contacts with the J domain through its
phenylalanines. All three previously known DNAJB6
mutations (of Phe89, Phe93 and Pro96) and mutations
reported here (of Phe91 and Phe100 and ΔG/F) are
strongly predicted to act, at least in part, through
disturbing these contacts. Our immunohistochemical
results, showing cytoplasmic protein aggregates in the
cytoplasm of many fibers in all patients, failed to
reveal a particular relation between histopathological
aspects and specific mutations [1, 2].
The clinical outcomes of the mutations while similar
(DNAJB6 myopathy) are not identical and not merely
in severity, but also in particularities of skeletal mus-
cles involved, i.e. lateral gastrocnemii with Phe91,
Phe100 and ΔG/F, and early bulbar involvement with
Phe100. This suggests a highly intricate and selective
activity of the protein at the G/F – J interface. A
glimpse into this has already been obtained through
the remarkable observation that at least the previously
known mutations affect the processing of particular,
and not all, conformers of target misfolding proteins
[9]. Understanding the precise molecular mechanisms
Ruggieri et al. Acta Neuropathologica Communications  (2015) 3:44 Page 12 of 14
through which DNAJB6 acts to process or stabilize misfold-
ing proteins are of keen interest for this and other protein
aggregation myopathies and for common neurological
diseases, including Alzheimer’s disease and frontotemporal
dementias. The current, and potentially future, mutations
in DNAJB6-myopathy patients will be crucial guides in
obtaining this knowledge.
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